Literature DB >> 32292673

Association of Autoimmune Hashimoto's Thyroiditis with Systemic Lupus Erythematosis.

Chetan B Kammari1, Subba Rao Daggubati2, Venu Madhav Konala3,4, Sreedhar Adapa5, Srikanth Naramala6.   

Abstract

SLE (systemic lupus erythematosus) can be associated with other autoimmune disorders with overlapping clinical symptoms. We present a case of a 22-year-old male with recurring exertional dyspnea, chest pain, dry cough and chills, which on further testing revealed large pericardial effusion and bilateral pleural effusions along with laboratory abnormalities consistent with a diagnosis of overlap of SLE with serositis and Hashimoto's thyroiditis. SLE patients with underlying hypothyroidism are slow to respond to standard therapy unless the underlying hypothyroidism is adequately treated.
Copyright © 2020, Kammari et al.

Entities:  

Keywords:  hashimotos thyroiditis; pericardial effusion; pleural effusion; sle

Year:  2020        PMID: 32292673      PMCID: PMC7152570          DOI: 10.7759/cureus.7261

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


Introduction

Pericardial and pleural effusions are some of the manifestations of serositis in SLE (systemic lupus erythematosus). Patients with SLE also have other associated autoimmune disorders with overlapping clinical symptoms. Our case highlights the importance of evaluating other differentials, especially hypothyroidism, which could also be present concurrently and contribute to the symptoms. SLE patients with underlying hypothyroidism are slow to respond to standard therapy unless the underlying hypothyroidism is adequately treated [1].

Case presentation

The patient is a 22-year-old male, chronic smoker, with no significant past medical history, with recent pneumonia associated with pleural and pericardial effusion, treated four weeks ago. He presented to the emergency department with recurring exertional dyspnea, chest pain, dry cough, and chills. The patient has a family history positive for mother having lupus and hypothyroidism. The initial chest x-ray showed cardiomegaly and bilateral recurrent pleural effusion. His d-dimer was elevated at 2.81 (0.19-0.50 mg/l) with negative bilateral lower extremity venous doppler. He had a computed tomography angiography (CTA) of the chest, which was negative for pulmonary emboli but showed large pericardial and bilateral pleural effusions (Figures 1-3). Electrocardiography (EKG) showed sinus rhythm and troponins were negative. Labs were not suggestive of any infection (Table 1). Urinalysis negative for proteinuria and urine protein/creatinine ratio not suggestive of lupus nephritis. Immunological work-up showed homogenous pattern antinuclear antibodies (ANA) and positive anti-double-stranded DNA, with normal complement levels and liver function tests. Rheumatoid factor, anti-RNP (ribonuclear protein antibody), anti-Jo, and anti-Sm antibodies were negative ruling out other etiologies. Thyroid-stimulating hormone (TSH) was elevated at 134 (0.358-3.740 uIU/ml), low T4 0.12 (0.76-1.46 ng/dl) with low T3 <0.5 (2.18-3.98 pg/ml). Thyroid peroxidase (TPO) and thyroglobulin antibodies were positive suggestive of autoimmune Hashimoto's thyroiditis. No goiter was noted on the clinical exam. The patient's presentation was consistent with an overlap of SLE with serositis and Hashimoto's thyroiditis. Cardiothoracic surgery was consulted, and the patient had bilateral chest tubes insertion with pericardial window placement. The patient was started on tapering steroid therapy along with levothyroxine supplementation. Cytology from the pericardial fluid showed reactive cells with scant inflammation and was negative for any malignancy. He had good clinical improvement with the eventual removal of the chest tubes. The patient was advised to follow up with rheumatology and endocrinology after discharge. Post-discharge follow up showed continued clinical improvement.
Figure 1

Computed tomography of chest (mediastinal window) showing pericardial effusion and bilateral pleural effusion

Arrows pointing pleural and pericardial effusion

Figure 3

Computed tomography of chest (coronal view) showing pericardial effusion and bilateral pleural effusion

Arrows pointing pleural and pericardial effusion

Table 1

Laboratory findings

ESR - erythrocyte sedimentation rate; CRP - C-reactive protein; ANA - anti-nuclear antibody, Anti-DsDNA - anti-double-stranded DNA; C3, C4 - complement levels 3, 4; LFT - liver function tests; RF/Anti-CCP - rheumatoid factor/cyclic citrullinated peptide; Anti-RNP - anti ribonucleo protein; TSH - thyroid stimulating hormone; T3, T4 - thyroid hormone 3, 4; TPO - thyroid peroxidase

Laboratory findings  
ESR 52 (0-15mm/hr)
CRP 76 (<3.0 mg/l)
ANA Positive homogenous pattern. 1:320 (normal <1:80)
Anti-DsDNA 65 (0-9)
C3 levels 141 (82-167 mg/dl)
C4 levels 18 (14-44 mg/dl)
LFT’s Normal limits
RF/Anti-CCP 13 (<15 IU/ml)/ 11 (0-19)
Anti RNP <0.2
Anti-Jo <0.2
Anti-Sm <0.2
TSH 134 (0.358-3.740 uUI/ml
T3 <0.5 (2.18 -3.98 Pg/ml)
T4 0.12 (0.76-1.46 ng/dl)
TPO 245 (0-34 IU/ml)
Thyroglobulin 352 (0-0.9 IU/ml)
Urine protein/creatinine ratio 5.6 (0-200)
Urine microalbumin/creatinine ratio 5.6 (0-30)

Computed tomography of chest (mediastinal window) showing pericardial effusion and bilateral pleural effusion

Arrows pointing pleural and pericardial effusion

Computed tomography of chest (lung window) showing pericardial effusion and bilateral pleural effusion

Arrows pointing pleural and pericardial effusion

Computed tomography of chest (coronal view) showing pericardial effusion and bilateral pleural effusion

Arrows pointing pleural and pericardial effusion

Laboratory findings

ESR - erythrocyte sedimentation rate; CRP - C-reactive protein; ANA - anti-nuclear antibody, Anti-DsDNA - anti-double-stranded DNA; C3, C4 - complement levels 3, 4; LFT - liver function tests; RF/Anti-CCP - rheumatoid factor/cyclic citrullinated peptide; Anti-RNP - anti ribonucleo protein; TSH - thyroid stimulating hormone; T3, T4 - thyroid hormone 3, 4; TPO - thyroid peroxidase

Discussion

SLE is one of the autoimmune disorders with variable presentation and multisystem involvement. Sometimes it can present in conjugation with other autoimmune disorders, which are underdiagnosed due to overlap with clinical and radiology findings [2, 3]. Autoimmune thyroiditis, especially Hashimoto's, is one such manifestation. Patient with SLE are more prone to thyroid problems compared to the controls and is usually more so in those having overlap syndrome [4, 5]. They can have positive thyroid antibodies with or without overt thyroid manifestations [6]. it predominantly manifests in patients with SLE and Hashimoto's during the hypothyroid state rather than hyperthyroid, suggesting that the initial hyperthyroid state could be obscured [7]. Pericardial effusion is one of the common cardiac manifestations of the hypothyroid state of Hashimoto's [8-10]. Our case highlights the patient whose hypothyroidism was subclinical and undiagnosed until the severe manifestations were evident [11]. LE (lupus erythematosus) cell detection assay used to be done in the past, which is sometimes seen in effusions from SLE, which can help differentiate SLE from other causes of pericardial effusion [12]. LE cell detection may be especially encountered with an uncommon presentation [13].

Conclusions

Patients with serositis need to be evaluated for other coexistent autoimmune disorders. This case highlights autoimmune hypothyroidism that can manifest as pericardial effusion, which needs to be considered when treating patients with SLE and pericarditis. LE cell detection in the fluid analysis may help differentiate SLE from other causes of serositis in some of the cases. Patients with untreated hypothyroidism are slow to respond to standard SLE treatment.
  12 in total

Review 1.  Review of major endocrine abnormalities in patients with systemic lupus erythematosus.

Authors:  Candido Muñoz; David A Isenberg
Journal:  Clin Exp Rheumatol       Date:  2019-06-06       Impact factor: 4.473

2.  Subclinical hypothyroidism is a risk factor for delayed clinical complete response in patients with systemic lupus erythematosus (SLE).

Authors:  Lin Dong; Liu Jia; Xuezhi Hong; Guangliang Chen; Hanyou Mo
Journal:  Int J Clin Exp Med       Date:  2014-09-15

3.  Pericardial effusion in hypothyroidism.

Authors:  C A Hardisty; D R Naik; D S Munro
Journal:  Clin Endocrinol (Oxf)       Date:  1980-10       Impact factor: 3.478

4.  Systemic lupus erythematosus and thyroid disease: A 10-year study.

Authors:  Wen-Ya Lin; Chia-Li Chang; Lin-Shien Fu; Ching-Heng Lin; Heng-Kuei Lin
Journal:  J Microbiol Immunol Infect       Date:  2014-05-26       Impact factor: 4.399

5.  Prevalence of thyroid autoantibodies in patients with systematic autoimmune rheumatic diseases. Cross-sectional study.

Authors:  Rayana Taques Posselt; Vinícius Nicolelli Coelho; Danieli Cristina Pigozzo; Marcela Idalia Guerrer; Marília da Cruz Fagundes; Renato Nisihara; Thelma Larocca Skare
Journal:  Sao Paulo Med J       Date:  2017 Nov-Dec       Impact factor: 1.044

6.  Association between systemic lupus erythematosus and thyroid dysfunction: a meta-analysis.

Authors:  W Luo; P Mao; L Zhang; Z Yang
Journal:  Lupus       Date:  2018-11       Impact factor: 2.911

Review 7.  Hypothyroidism among SLE patients: Case-control study.

Authors:  Abdulla Watad; Naim Mahroum; Aaron Whitby; Smadar Gertel; Doron Comaneshter; Arnon D Cohen; Howard Amital
Journal:  Autoimmun Rev       Date:  2016-01-28       Impact factor: 9.754

8.  Prevalence of thyroid dysfunction in systemic lupus erythematosus.

Authors:  Simone Appenzeller; Ana T Pallone; Ricardo A Natalin; Lilian T L Costallat
Journal:  J Clin Rheumatol       Date:  2009-04       Impact factor: 3.517

9.  Detection of lupus erythematosus cells in pleural effusion: An unusual presentation of systemic lupus erythematosus.

Authors:  Sushma Gulhane; Nitin Gangane
Journal:  J Cytol       Date:  2012-01       Impact factor: 1.000

10.  Pericardial Effusion as a Presenting Symptom of Hashimoto Thyroiditis: A Case Report.

Authors:  Alberto Leonardi; Laura Penta; Marta Cofini; Lucia Lanciotti; Nicola Principi; Susanna Esposito
Journal:  Int J Environ Res Public Health       Date:  2017-12-14       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.